Please login to the form below

Not currently logged in
Email:
Password:

EGFR inhibitor

This page shows the latest EGFR inhibitor news and features for those working in and with pharma, biotech and healthcare.

FDA approval gained, Pfizer sets sights on first-line NSCLC market

FDA approval gained, Pfizer sets sights on first-line NSCLC market

Vizimpro could challenge Tagrisso, survival data will be key. Pfizer’s gruelling trek to bring EGFR inhibitor dacomitinib to market has finally paid off, with the FDA approving it as a ... The second-generation EGFR tyrosine kinase inhibitor has been

Latest news

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    Elunate will have to go up against well-established oral drugs like Bayer’s multikinase inhibitor Stivarga (regorafenib) and Taiho Oncology’s Lonsurf (trifluridine/tipiracil) in the third-line setting. ... alongside AZ’s EGFR inhibitor Iressa

  • AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

    for patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). ... recurrent NSCLC that is resistant to existing first-line EGFR-inhibitor medicines.

  • Pfizer’s flat sales focus investor attention on M&A Pfizer’s flat sales focus investor attention on M&A

    Among the highlights cited by Read on the call were oncology drugs talazoparib - a PARP inhibitor due for filing shortly for breast cancer - along with ALK/ROS1 inhibitor lorlatinib and EGFR ... inhibitor dacomitinib for lung cancer, which are due for

  • AZ’s immuno-oncology combo fails another lung cancer trial AZ’s immuno-oncology combo fails another lung cancer trial

    There is no doubt, however, that the study raises another question mark over the role of CTLA4 inhibitor tremelimumab. ... There was better news for AZ in cancer last week, after the company picked up FDA approval for its EGFR inhibitor Tagrisso

  • AZ makes case for first-line Tagrisso therapy in lung cancer AZ makes case for first-line Tagrisso therapy in lung cancer

    Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva. ... AstraZeneca says that new data from its FLAURA trial of EGFR inhibitor Tagrisso makes a compelling argument that the drug should be use ahead of other dugs in

More from news
Approximately 1 fully matching, plus 58 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics